2023 saw a record use of CVRs in pharma, biotech, and life sciences M&A deals. The program will review the key terms in CVRs in deals announced in 2023 and the key issues that arise in the negotiation of CVR agreements.
Materials
The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.
